

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2873625

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
FLORIDA ATLANTIC UNIVERSITY	07/11/2013
RECEIVING PARTY DATA	
Name:	FLORIDA ATLANTIC UNIVERSITY RESEARCH CORPORATION
Street Address:	777 GLADES ROAD
City:	BOCA RATON
State/Country:	FLORIDA
Postal Code:	33431
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13246527
CORRESPONDENCE DATA	
Fax Number:	(561)768-7817
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	561-935-6690
Email:	flanderip@gmail.com
Correspondent Name:	FERRIS H. LANDER
Address Line 1:	FERRIS H. LANDER, INC.
Address Line 2:	P.O. BOX 31166
Address Line 4:	PALM BEACH GARDENS, FLORIDA 33420
ATTORNEY DOCKET NUMBER:	1087U.001
NAME OF SUBMITTER:	FERRIS H. LANDER
SIGNATURE:	/Ferris H. Lander/
DATE SIGNED:	05/28/2014
Total Attachments: 3	
source=60621_Assignment FAU_FAURC#page1.tif	
source=60621_Assignment FAU_FAURC#page2.tif	
source=60621_Assignment FAU_FAURC#page3.tif	

ASSIGNMENT OF PATENT RIGHTS

This is an Agreement, entered into on 11th day of July, 2013 between FLORIDA ATLANTIC UNIVERSITY Board of Trustees, referred to as "FAU" and FLORIDA ATLANTIC UNIVERSITY RESEARCH CORPORATION, a Florida non-profit corporation, and direct support organization of Florida Atlantic University, referred to as the "Research Corporation".

In consideration of the mutual promises and covenants contained in this Agreement, and other good and valuable consideration, the receipt and adequacy of which are acknowledged, the Parties agree as follows:

1. FAU assigns and conveys to Research Corporation all licensing rights and patent rights FAU has or may have in connection with "*Materials and Methods for the Treatment of Pathological Neovascularization*" ("Intellectual Property"), a copy of which is attached hereto and incorporated by this reference as Exhibit A, and which has been initially developed by FAU employee(s) Janet Blanks, Ph.D., Howard Prentice, Ph.D. and Kathleen Dorey, Ph.D. (FAU employee at the time of disclosure). FAU and Research Corporation acknowledge and agree that the Intellectual property is being assigned to the Research Corporation for the benefit of FAU.

2. In connection with the Intellectual Property, the Parties agree that:

a. Expenses, as defined by the FAU Intellectual Property Policy in effect at the time the Intellectual Property is licensed ("Expenses"), incurred by FAU in connection with the Intellectual Property will be reimbursed to FAU by Research Corporation from income generated by the Intellectual Property prior to any distributions under the FAU Intellectual Property Policy.

b. Expenses, incurred by the Research Corporation in connection with the Intellectual Property will be reimbursed to the Research Corporation from income generated by the Intellectual Property after reimbursement of expenses to FAU but prior to distribution of any income or royalties under the FAU Intellectual Property Policy.

c. Any net income remaining after all Expenses have been satisfied in connection with the Intellectual Property shall be distributed pursuant to the FAU Intellectual Property Policy in effect at the time the Intellectual Property is licensed or pursuant to such other agreement between the Parties.

3. The term of this Agreement is for a period of twenty (20) years, beginning with the date of this Agreement, or for the term of any license agreement entered into by the Research Corporation in reference to this Intellectual Property, whichever is longer.

4. This Agreement will be governed by the laws of Florida.

5. Nothing in this Agreement shall inure to or be interpreted to inure to the benefit of any third party.

IN WITNESS OF THE FOREGOING, the Parties sign this Agreement to be effective on the day and year first written above.


FLORIDA ATLANTIC UNIVERSITY


JoAnn Moretti, MPA
Director, Sponsored Programs

Date:


7.11.13

FLORIDA ATLANTIC UNIVERSITY
RESEARCH CORPORATION


Barry T. Rosson, Ph.D.
President of FAURC

Date:

7.18.13

APPROVED AS TO FORM
AND LEGALITY
General Counsel
Florida Atlantic University

6/26/13
PATENT

REEL: 032976 FRAME: 0983

EXHIBIT A

**FAU 201024 - Materials and Methods for the Treatment of Pathological Neovascularization
U.S. Utility Patent Application 13/246,527**

Inventors:

Janet Blanks, Ph.D.

Howard Prentice, Ph.D.

C. Kathleen Dorey, Ph.D. (FAU employee at the time of disclosure)

(Patent publication US 2012/0077870, March 29, 2012 - copy attached)



US 20120077870A1

(19) **United States**(12) **Patent Application Publication**
Blanks et al.(10) **Pub. No.: US 2012/0077870 A1**(43) **Pub. Date: Mar. 29, 2012**(54) **MATERIALS AND METHODS FOR THE
TREATMENT OF PATHOLOGICAL
NEOVASCULARIZATION IN THE EYE****Publication Classification**

(51) **Int. Cl.**
A61K 48/00 (2006.01)
A61P 27/02 (2006.01)
A61P 9/00 (2006.01)
C12N 15/86 (2006.01)
(52) **U.S. Cl.** **514/44 R; 435/320.1**
(57) **ABSTRACT**

(76) **Inventors:** **Janet C. Blanks**, Boca Raton, FL
(US); **Howard M. Prentice**, Boca
Raton, FL (US); **C. Kathleen**
Dorey, Roanoke, VA (US)

(21) **Appl. No.: 13/246,527**(22) **Filed: Sep. 27, 2011****Related U.S. Application Data**(60) **Provisional application No. 61/386,889, filed on Sep.
27, 2010.**

The subject invention provides materials and methods useful in safely and effectively preventing pathological proliferation of blood vessels. The prevention of the over-proliferation of blood vessels according to the subject invention is particularly advantageous for treatment of certain ocular conditions including age-related macular degeneration (AMD), retinopathy of prematurity (ROP) and diabetic retinopathy. In preferred embodiments, the subject invention provides materials and methods for effective treatment of pathological ocular neovascularization using gene therapy. In a specific embodiment the materials and methods of the subject invention can be used to treat AMD.

